Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)Market Beat·Jul 23 at 07:06 AMZNTL+0.22%JPM-0.12%
Cross-Currents in US Equities: From AI Integration Triumphs to Crypto CasualtiesGlobal Report·Jul 19 at 04:13 AMEPAM+5.91%BTM0.00%
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Fridaybenzinga_article·Jul 17 at 09:09 AMTRV+1.71%ZNTL+0.22%
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | ZNTL Stock NewsStockTitan·Jul 17 at 07:15 AMZNTL+0.22%
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL)Tip Ranks·Jul 17 at 03:55 AMZNTL+0.22%
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock NewsStockTitan·Jun 1 at 08:00 AMZNTL+0.22%
Zentalis To Present Part 1 Phase 1b MUIR Trial Results Of Azenosertib At ASCO 2026nasdaq·May 22 at 05:15 AMZNTL+0.22%BIB+0.53%
Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg CohortTradingView·May 21 at 04:33 PMZNTL+0.22%ARKG-0.79%
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock NewsStockTitan·May 21 at 08:40 AMZNTL+0.22%IBB+0.44%
Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)Tip Ranks·May 13 at 10:16 AMZNTL+0.22%XBI-1.57%
